Global Donepezil Market Strategic Research Report

Scope of the Report

The global Donepezil market size is predicted to grow from US$ 907 million in 2025 to US$ 1,010 million in 2032; it is expected to grow at a CAGR of 1.6% from 2026 to 2032.

Donepezil is a selective and reversible acetylcholinesterase inhibitor primarily used to treat cognitive impairment in patients with Alzheimer’s disease (AD). By inhibiting the breakdown of acetylcholine in the brain, it enhances neurotransmitter levels, thereby improving memory, learning, and behavioral functions. Since its launch in the 1990s, Donepezil has become one of the most widely used therapeutic agents for Alzheimer’s disease globally, available in oral tablets, orally disintegrating tablets, and transdermal patch formulations. It features stable pharmacological properties and a favorable safety profile, offering good compliance in long-term management of mild to moderate AD. With population aging and the rising prevalence of neurodegenerative disorders, the market value of Donepezil continues to expand, consolidating its position as a cornerstone drug in the neurological therapeutics sector.In 2024, global Donepezil production reached approximately 1772 m units, with an average global market price of around US$ 0.5 perunit.The average gross profit margin for this product is 60%.

With the acceleration of global population aging and improved diagnosis rates of Alzheimer’s disease, the Donepezil market is entering a new phase of growth. Many healthcare systems have integrated cognitive disorder management into chronic disease programs, increasing accessibility and reimbursement coverage. In addition, formulation innovations such as orally disintegrating tablets and long-acting transdermal patches enhance patient convenience and compliance, creating new competitive advantages. Meanwhile, faster drug registration and generic approval processes in emerging markets—especially across Asia—are opening strategic windows for local players, driving further globalization of the supply chain.Despite its growth potential, Donepezil faces challenges from patent expirations and intensified generic competition. Stricter drug tendering systems in several countries continue to push down average prices, squeezing profit margins. Furthermore, the emergence of novel Alzheimer’s therapies—such as β-amyloid antibodies and tau protein modulators—may reshape the therapeutic landscape, posing potential substitution threats. Increasing regulatory requirements for quality consistency and pharmacovigilance also demand more advanced production and compliance systems from manufacturers.Clinically, Donepezil remains one of the first-line treatments for mild to moderate Alzheimer’s disease, particularly in primary care and long-term care facilities. As public awareness of cognitive disorders grows and early screening expands, the number of mild cases continues to rise, ensuring stable demand. National healthcare policies increasingly encourage the use of generic medications, benefiting domestic manufacturers. Meanwhile, research into new indications—such as Parkinson’s-related dementia and vascular cognitive impairment—offers new growth momentum for the market.Key raw materials for Donepezil include piperidine intermediates, benzothiazole derivatives, and multiple organic solvents and catalysts required in multistep synthesis. With tightening environmental regulations, optimization of synthetic pathways for core intermediates has become a cost-control priority. The upstream sector is moving toward high-purity, high-yield, and greener synthesis processes to meet pharmacopeia standards in Europe, the U.S., and Japan. Leading global suppliers are integrating APIs and finished dosage forms to ensure stable raw material supply and mitigate production volatility.

This report presents a comprehensive overview of the global Donepezil market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 5mg
• 10mg
• 23mg

Segment by Application

• Hospitals
• Clinics
• Drugstore

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Donepezil market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospitals, Clinics, Drugstore evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact